Navigation Links
David S. Tierney, M.D., Joins Thomas, McNerney & Partners as Entrepreneur-In-Residence
Date:4/21/2008

David S. Tierney, M.D. joins Connecticut office to Focus on Specialty

Pharmaceuticals, Drug Delivery and Biotechnology

STAMFORD, Conn., April 21 /PRNewswire/ -- Thomas, McNerney & Partners, LLC, a health care venture capital firm that invests in life science and medical technology companies, today announced that David S. Tierney, M.D., has joined as an Entrepreneur-in-Residence in the firm's Connecticut office. Most recently, Dr. Tierney was president and chief executive officer of Valera Pharmaceuticals, Inc., a fully-integrated specialty pharmaceutical and drug delivery company, which was acquired by Indevus Pharmaceuticals.

"David's background is perfect for this role. He has experience as a chief executive with an entrepreneurial company, and also as a drug developer in both specialty and mainstream markets," said Alex Zisson, partner. "We're looking forward to working with David on ideas for new companies and potential investments."

Dr. Tierney has more than 18 years of drug development experience, most recently as chief executive officer of Valera Pharmaceuticals, Inc. Prior to joining Valera, he was president of Biovail Technologies, overseeing all research, development, clinical and regulatory affairs. Prior to Biovail, Dr. Tierney was senior vice president, drug development for Roberts Pharmaceuticals, which was acquired by Shire plc. He began his pharmaceutical career at Elan Corporation where he spent eight years in various drug development roles. Dr. Tierney is also a member of the board of directors of Catalyst Pharmaceuticals Partners, Inc, Nexmed Inc and serves as chairman of the board of directors of Bioject Inc.

"Thomas, McNerney & Partners has a great platform in biopharmaceuticals," said Dr. Tierney. "The partners have many contacts in industry and academia, and I'm confident that I'll be able to add value to their investment process while we work together to identify my next operating role."

About Thomas, McNerney & Partners

Thomas, McNerney & Partners is a health care venture capital firm with approximately $600 million under management focused on investing in life science and medical technology companies at all stages of development. In addition to helping entrepreneurs launch companies with seed and early stage funding, the firm provides growth capital to emerging companies to advance clinical development or for product commercialization. Thomas, McNerney & Partners also is involved in spinning out products and divisions from major medical device and pharmaceutical companies, consolidating companies through roll-up strategies and participating in structured financings for public companies as well as recapitalizations. The firm is targeting investments in the pharmaceutical, medical device, biotechnology and diagnostic sectors and in other areas utilizing medical technology innovation. The firm has offices in Stamford, Minneapolis and San Francisco. For further information, please visit http://www.tm-partners.com.


'/>"/>
SOURCE Thomas, McNerney & Partners, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NSF International Acquires David Begg Associates
2. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
3. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
4. David Barker, Former Illumina CSO, Joins GenVaults Scientific Advisory Board
5. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
6. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
7. Immunosyn Corporation Names G. David Criner as CFO
8. Pasteuria Bioscience Taps New CEO David N. Duncan
9. David Mott Appointed Non Executive Director at Shire
10. Stereotaxis Appoints David Burkhardt, M.D. as Chief Medical Officer
11. Transgenomic Appoints David Pauluzzi to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... ... is pleased to announce the company is now a certified iMedNet eClinical and ... software certification enables the company’s clinical research team to build, customize and manage ...
(Date:4/25/2017)... ... April 25, 2017 , ... Covalent Metrology ... Analytical Services unit provides high-quality data to clients, both faster and ... of receipt. There are no price premiums, and customers are welcome to participate ...
(Date:4/24/2017)... , April 24, 2017  Dante Labs announced today the ... EUR 850 (ca. $900). While American individuals have been able ... time Europeans can access WGS below EUR 1,000. ... to leveraging genetic information to make informed decisions about disease ... ...
(Date:4/21/2017)... ... April 21, 2017 , ... The University of Connecticut, in ... to three startups through the UConn Innovation Fund. The $1.5 million UConn Innovation ... with UConn. , The UConn Innovation Fund provides investments of up to $100,000 ...
Breaking Biology Technology:
(Date:4/13/2017)... 13, 2017 UBM,s Advanced Design and Manufacturing ... feature emerging and evolving technology through its 3D Printing ... run alongside the expo portion of the event and ... demonstrations focused on trending topics within 3D printing and ... manufacturing event will take place June 13-15, 2017 at the ...
(Date:4/11/2017)... Apr. 11, 2017 Research and Markets has ... report to their offering. ... The global eye tracking market to grow at a CAGR of ... Eye Tracking Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
Breaking Biology News(10 mins):